Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 3/20 | 0.39 |
| ▸ | BMI1 | P35226 | 3/20 | 0.34 |
| ▸ | GALR1 | P47211 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.33 |
| ▸ | TUBB | P07437 | 4/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747825 | 0.91 | GALR2 (0.37) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16740288 | 0.88 | PKM (0.43) | CDK2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18103451 | 0.87 | PKM (0.35) | CDK2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16747822 | 0.86 | GALR2 (0.41) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16740301 | 0.86 | TUBB4A (0.44) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16740085 | 0.85 | IRAK4 (0.43) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16740327 | 0.84 | GALR2 (0.40) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16747821 | 0.83 | GALR2 (0.39) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL18094393 | 0.82 | PKM (0.39) | GALR2BMI1GALR1TUBB4ATUBB | |
| SCHEMBL16740299 | 0.82 | BMI1 (0.40) | GALR2BMI1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | GALR2 4615/4885BMI1 1/4885GALR1 4068/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | GALR2 4615/4885BMI1 1/4885GALR1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.